Sarepta Therapeutics Inc.'s (SRPT) upcoming R&D day will be a look at the future of the company as the company plans to showcase its deep pipeline of candidates across five therapeutic modalities, including gene therapy, gene editing, and its next-generation PPMO RNA chemistry. This diverse array of treatments means that Sarepta can cherry pick the most promising of the bunch to focus on, as it partners with leading companies in the DMD space, often with exclusive options for commercialization or acquisition in place. Sarepta's considerable cash hoard, along with its potentially fast growing sales base, with additional Duchenne Muscular Dystrophy (DMD) candidates coming to potential commercialization in 2019 and beyond in the US and possibly Europe, means that it has the firepower to rapidly focus on commercialization of its best candidates, or to make a major acquisition for this $6 billion market cap company.
Sarepta's R&D day will feature several notable speakers, with the most interesting to me, that of Louise Rodino-Klapac, Ph.D, who is developing gene therapies for various forms of limb-girdle muscular dystrophies at the Center for Gene Therapy at Nationwide Children's Hospital. She is the lead on Sarepta's latest partnership with privately held Myonexus Therapeutics, and will give a formal presentation at R&D day on its lead candidate MYO-101, along with information on the start of clinical trials for the candidate which are scheduled to begin mid-year.

